Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease

A. L. Pukhalsky, G. V. Shmarina, S. N. Kokarovtseva, N. I. Kapranov, L. A. Shabalova (Moscow, Russia)

Source: Annual Congress 2002 - Respiratory problems and new ways of evaluating the patient with cystic fibrosis
Session: Respiratory problems and new ways of evaluating the patient with cystic fibrosis
Session type: Thematic Poster Session
Number: 3283
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. L. Pukhalsky, G. V. Shmarina, S. N. Kokarovtseva, N. I. Kapranov, L. A. Shabalova (Moscow, Russia). Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease. Eur Respir J 2002; 20: Suppl. 38, 3283

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Factors affecting progression of lung disease among patients with cystic fibrosis
Source: International Congress 2019 – Physiology of cystic fibrosis
Year: 2019


Early determinants of lung disease in children with cystic fibrosis
Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology
Year: 2020




Relations between the sinonasal development and the lung disease in cystic fibrosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 103s
Year: 2005

Elucidating progression of early cystic fibrosis lung disease
Source: Eur Respir J, 50 (5) 1701916; 10.1183/13993003.01916-2017
Year: 2017



Early cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 77-87
Year: 2014


Risk factors for lung disease progression in children with cystic fibrosis
Source: Eur Respir J, 51 (6) 1702509; 10.1183/13993003.02509-2017
Year: 2018



Risk factors for lung disease progression in children with cystic fibrosis
Source: Eur Respir J, 52 (4) 1801492; 10.1183/13993003.01492-2018
Year: 2018



Inflammatory markers can predict pulmonary exacerbations of cystic fibrosis
Source: International Congress 2017 – Cystic fibrosis: monitoring and biomarkers
Year: 2017

Pathophysiology of cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 1-13
Year: 2014


Mechanisms and markers of airway inflammation in cystic fibrosis
Source: Eur Respir J 2002; 19: 333-340
Year: 2002



Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2008; 32: 170-174
Year: 2008



The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis
Source: Eur Respir J, 54 (1) 1801771; 10.1183/13993003.01771-2018
Year: 2019



Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease
Source: Eur Respir J, 57 (2) 2003079; 10.1183/13993003.03079-2020
Year: 2021



The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype
Source: Eur Respir Rev, 27 (150) 180077; 10.1183/16000617.0077-2018
Year: 2018



The clinical value of surgical lung biopsy in 166 patients with suspected interstitial lung disease
Source: International Congress 2015 – New insights into IIPs
Year: 2015

Inflammatory markers in cystic fibrosis patients with different values of pulmonary function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 528s
Year: 2002

The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 327s
Year: 2006

The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013

Genotype and progressive lung damage in adult cystic fibrosis patients
Source: Eur Respir J 2003; 22: Suppl. 45, 502s
Year: 2003